Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 2/20 | 0.49 |
| ▸ | HRAS | P01112 | 11/20 | 0.49 |
| ▸ | ESR1 | P03372 | 11/20 | 0.49 |
| ▸ | ESR2 | Q92731 | 11/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | AR | P10275 | 6/20 | 0.46 |
| ▸ | DNM1L | O00429 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26643173 | 0.93 | HRAS (0.50) | TOP1HRASESR1ESR2KDM4E | |
| SCHEMBL26643090 | 0.91 | HRAS (0.48) | TOP1HRASESR1ESR2KDM4E | |
| SCHEMBL26643253 | 0.91 | HRAS (0.48) | TOP1HRASESR1ESR2KDM4E | |
| SCHEMBL26643222 | 0.85 | HRAS (0.56) | TOP1HRASESR1ESR2KDM4E | |
| SCHEMBL26643272 | 0.83 | HRAS (0.52) | TOP1HRASESR1ESR2KDM4E | |
| Hydrochloric Acid SCHEMBL10693519 | 0.83 | KDM4E (0.69) | TOP1HRASESR1ESR2KDM4E | |
| SCHEMBL26643327 | 0.83 | HRAS (0.53) | TOP1HRASESR1ESR2KDM4E | |
| Hydrochloric Acid SCHEMBL10690247 | 0.83 | KDM4E (0.69) | TOP1HRASESR1ESR2KDM4E | |
| SCHEMBL31516504 | 0.83 | HRAS (0.51) | TOP1HRASESR1ESR2KDM4E | |
| SCHEMBL26643180 | 0.81 | ALDH1A1 (0.48) | TOP1HRASESR1ESR2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250313546-A1 | NUCLEIC ACID BINDERS | UNIVERSITY OF STRATHCLYDE (GB) | 2025-10-09 | — | — | US | disclosed |
| EP-4522588-A1 | NUCLEIC ACID BINDERS | University of Strathclyde (GB) | 2025-03-19 | — | — | EP | disclosed |
| CN-119585239-A | Nucleic acid binding agents | 斯特拉斯克莱德大学 | 2025-03-07 | — | — | CN | disclosed |
| WO-2023218194-A1 | NUCLEIC ACID BINDERS | UNIVERSITY OF STRATHCLYDE (GB) | 2023-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250313546-A1 | NUCLEIC ACID BINDERS | ZFR, NSUN3, POLI | TOP1 322/4885HRAS 830/4885ESR1 1271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.